Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2018 | Pembrolizumab for frontline head and neck cancer: KEYNOTE-048 results

Barbara Burtness • 22 Oct 2018
ESMO 2018
Head and Neck Cancer Pembrolizumab
KEYNOTE-048

The latest news in head and neck cancer was presented at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany. Here, Barbara Burtness, MD, of Yale School of Medicine, New Haven, CT, presents the breaking news from the meeting. Prof. Burtness covers the Phase III KEYNOTE-048 trial (NCT02358031) of pembrolizumab for the frontline treatment of recurrent/metastatic head and neck squamous cell carcinoma.

More from Barbara Burtness

0:47
Novel KRAS-targeting agents on the horizon
Barbara Burtness • 7 Aug 2022
0:35
Data on KRAS inhibitors in lung cancer at WCLC 2022
Barbara Burtness • 7 Aug 2022
10:08
Evolving role of HER2 targeted therapies in gastroesophageal cancers
Barbara Burtness • 28 May 2020
4:11
CDKN2A and TP53 mutation in HPV-negative HNSCC
Barbara Burtness • 28 May 2020

Related Videos

1:03
Challenges in implementing liquid biopsies for head and neck cancer
Mouadh Barbirou • 7 Apr 2024
2:43
Molecular profiling of tumor biomarkers in head and neck cancer
Mouadh Barbirou • 7 Apr 2024
1:40
The future of squamous cell carcinoma research at ESMO Asia 2023
Brian Henick • 6 Dec 2023
0:54
The role of immunotherapy in PD-L1 low advanced squamous cell carcinoma
Brian Henick • 6 Dec 2023
The content of VJOncology is intended for healthcare professionals